- Poster presentation
- Open Access
Type 1 and 3 collagen production by bone marrow mesenchymal stromal cells is suppressed in vitro after exposure to sepsis patient serum
© Pernu et al.; 2015
- Published: 1 October 2015
- Severe Sepsis
- Mesenchymal Stromal Cell
- Sepsis Patient
- Chemiluminescence Immunoassay
- Bone Marrow MSCs
Severe sepsis is a systemic host response to invading pathogen with activated inflammation, coagulation and tissue remodelling cascades and consequent organ dysfunction. Despite modern intensive care, mortality in severe sepsis remains high. Mesenchymal stromal cells (MSCs) are known to have many anti-inflammatory features and contribute to the healing process. Many research groups have demonstrated good results using MSCs as an adjunctive treatment of sepsis in animal studies. Recently, a research group conducted a phase I clinical trial to test safety of MSCs on ARDS patients (). To date knowledge of sepsis influence on MSCs is scarce.
Our aim was to study the capability of MSCs to produce extracellular matrix components, type 1 and 3 collagens, when exposed to serum of septic patients in an experimental in vitro sepsis model.
Bone marrow MSCs (BM-MSC) were exposed to four different cell culture conditions: 1. Standard BM-MSC cell culture media (SCCM) with 20 % FBS, 2. SCCM with 20 % FBS added with 3 ng/ml TNF-alpha, 3. SCCM with 20 % human serum pooled from healthy volunteers (serum n = 8), 4. SCCM with 20 % human serum pooled from patients diagnosed with septic shock (serum n = 6). BM-MSCs were incubated for four days and the supernatant were collected and stored in -70° C until analysis. Production of type 1 and 3 collagens were determined by measuring the concentration of type 1 and 3 collagens N-terminal propeptide (PINP and PIIINP) from cell culture media. PINP concentration was determined with a chemiluminescence immunoassay (IDS iSYS, Immunodiagnostics Systems, Boldon, UK) and PIIINP concentration was determined with a radioimmunoassay (Orion Diagnostica, Espoo, Finland).
Serum from patients with severe sepsis suppresses the MSCs capability to produce collagen I and III in vitro. The PIIINP/PINP profile is also altered in favour of PIIINP over PINP. These results suggest that septic environment alters the extracellular matrix remodelling capability of MSCs, which in turn can alter tissue healing in vivo. This should be taken into consideration when using MSC therapy in severe sepsis.
Sigfrid Juselius Foundation, Oulu University Hospital's government allocated research funding.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.